Advocacy Articles
Clear filter
What HOPA Members Should Know About the End of the 2025 U.S. Government Shutdown
On Wednesday, November 12, Congress passed a continuing resolution to re-open the government after a record 43-day shutdown. Here's what HOPA members should know about the bill and what's happening next.
HOPA Endorses ISOPP & UICC Statement on Ensuring International Cancer Drug Quality and Equity
ISOPP and UICC recently released a statement calling for quality and equity of cancer treatments in sub-Saharan Africa. HOPA has joined with oncology and pharmacy organizations worldwide to endorse their statement.
Record-Breaking Hill Day Participation Brings HOPA Advocacy, Education to D.C.
HOPA members and staff were hard at work in the nation's capital for HOPA Hill Day on Tuesday, Sept. 30, discussing the hem/onc pharmacy profession and the important issues facing optimized cancer care across the nation.
HOPA and Coalition to Improve Access to Cancer Care Commend Reintroduction of Cancer Drug Parity Act
HOPA, along with the CIACC, recently voiced its support for the reintroduced Cancer Drug Parity Act, aiming to make oral and self-administered cancer treatments less expensive and more accessible.
Time to Complete Oncology Pharmacist Tasks: A Joint Opinion of HOPA and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network
HOPA and the Hematology/Oncology Practice and Research Network (PRN) of the ACCP published research producing the first comprehensive consensus statements on the average time for a U.S.-based oncology pharmacist to complete common care-related tasks.
Together We Can Save Cancer Research - and Lives
In the past two decades, extraordinary progress has been made in the fight against cancer. However, with Congress determined to reduce federal spending, entire cancer research, prevention, and surveillance programs are on the verge of elimination.